PALO ALTO, Calif. , June 27, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced data presented
- Data presented in oral presentation at ENDO 2022 on June 11 - Avexitide significantly reduced the number of hypoglycemia events and the amount of time spent in hypoglycemia - Study included patients who had undergone gastric bypass, vertical sleeve, total gastrectomy, or Nissen fundoplication
- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PALO ALTO, Calif. , June 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure
